p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

p53 Mutations in Human Cancers

1991 • 8,133 citations

The p53 tumour suppressor gene

1991 • 3,871 citations

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1991 • 3,493 citations

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

1991 • 2,447 citations

The p53 proto-oncogene can act as a suppressor of transformation

1989 • 2,019 citations

Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

1988 • 1,140 citations

Increased expression of mutant forms of p53 oncogene in primary lung cancer

1990 • 1,045 citations

Gain of function mutations in p53

1993 • 876 citations

Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

1993 • 827 citations

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.

1994 • 644 citations

NYVAC: A highly attenuated strain of vaccinia virus

1992 • 473 citations

p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts.

1991 • 455 citations

Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

1982 • 448 citations

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

1995 • 446 citations

Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

1990 • 409 citations

Targeting p53 as a general tumor antigen.

1995 • 315 citations

Activating Mutations for Transformation by p53 Produce a Gene Product That Forms an hsc70-p53 Complex with an Altered Half-Life

1988 • 298 citations

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

1993 • 267 citations

Induction of anti-self-immunity to cure cancer

1995 • 207 citations

Immunisation with canarypox virus expressing rabies glycoprotein

1992 • 184 citations

Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.

1993 • 173 citations

A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.

1993 • 171 citations

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.

1994 • 168 citations

Cloning and expression of foreign genes in vaccinia virus, using a host range selection system

1989 • 151 citations

Gene Transfer as Cancer Therapy

1995 • 142 citations

Complex of simian virus 40 large-T antigen and host 53,000-molecular-weight protein in monkey cells

1981 • 113 citations

H-2Dd exploits a four residue peptide binding motif.

1993 • 98 citations

Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer

1995 • 98 citations

Highly Attenuated Poxvirus Vectors

1992 • 89 citations

Identification of wild‐type and mutant p53 peptides binding to HLA‐A2 assessed by a peptide loading‐deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay

1994 • 72 citations

HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques

1995 • 70 citations

New strategies for active immunotherapy with genetically engineered tumor cells

1992 • 66 citations

Immunotherapeutic Strategies for Cancer Using Poxvirus Vectors

1993 • 17 citations